Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17574065 | 0.85 | DGAT1 (0.44) | DGAT1KCNN4SRCPRSS1CTSG | |
| SCHEMBL4304192 | 0.84 | DGAT1 (0.37) | DGAT1KCNN4LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL14959853 | 0.80 | DGAT1 (0.34) | DGAT1KCNN4TSHRNPSR1 | |
| SCHEMBL786780 | 0.80 | DGAT1 (0.41) | DGAT1KCNN4TSHR | |
| SCHEMBL22105961 | 0.79 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL13228527 | 0.79 | DGAT1 (0.37) | DGAT1TSHRNPSR1 | |
| SCHEMBL12690948 | 0.78 | DGAT1 (0.39) | DGAT1KCNN4TSHR | |
| SCHEMBL16807263 | 0.78 | DGAT1 (0.39) | DGAT1KCNN4TSHR | |
| SCHEMBL12690945 | 0.78 | DGAT1 (0.39) | DGAT1KCNN4TSHR | |
| SCHEMBL10093742 | 0.78 | DGAT1 (0.39) | DGAT1KCNN4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3673921-A1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxalta GmbH (CH) | 2020-07-01 | — | — | EP | disclosed |
| EP-2654794-B1 | MATERIALS AND METHODS FOR CONJUGATING A WATER SOLUBLE FATTY ACID DERIVATIVE TO A PROTEIN | Baxalta GmbH (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-20170136450-A1 | POLYMER CONTAINING CARBOXYL GROUP, PREPARATION METHOD AND APPLICATION THEREOF, SUPPORTED CATALYST AND PREPARATION METHODS THEREOF AND PREPARATION METHODS OF PENEM ANTIBIOTIC INTERMEDIATE | ASYMCHEM LABORATORIES (FUXIN) CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| WO-2011134538-A1 | DIYNE COMPOSITIONS | EVOLVA LTD (CH) | 2011-11-03 | — | — | WO | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033745-A2 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136450-A1 | POLYMER CONTAINING CARBOXYL GROUP, PREPARATION METHOD AND APPLICATION THEREOF, SUPPORTED CATALYST AND PREPARATION METHODS THEREOF AND PREPARATION METHODS OF PENEM ANTIBIOTIC INTERMEDIATE | PGM2, MGAM, MRPL21 | DGAT1 4368/4885KCNN4 948/4885LMNA 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.